Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rhenium (186Re) obisbemeda - Plus Therapeutics

Drug Profile

Rhenium (186Re) obisbemeda - Plus Therapeutics

Alternative Names: 186-Rheneium nanoliposome-Plus Therapeutics; 186RNL; Re-186; Rhenium-186 NanoLiposome; RNL™

Latest Information Update: 24 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Plus Therapeutics
  • Class Antineoplastics; Heavy metals; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Meningeal carcinomatosis
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioma
  • Phase I/II Meningeal carcinomatosis
  • Preclinical Brain cancer; Peritoneal cancer; Squamous cell cancer

Most Recent Events

  • 22 Apr 2024 Plus Therapeutics plans a phase I trial for Brain cancer (In children, In infants, In neonates) in the second half of 2024
  • 11 Mar 2024 Updated adverse events data from the phase I ReSPECT-LM trial in Meningeal carcinomatosis released by Plus Therapeutics
  • 05 Mar 2024 Plus Therapeutics plans to meet US FDA to align on the design for a pivotal Phase II/III ReSPECT-LM trial for the treatment of breast cancer with leptomeningeal metastases
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top